Boston Scientific requests more time as enrollment issues delay MultiSense trial

Medical device giant Boston Scientific asks the FCC for permission to continue using restricted radio frequencies as the company attempts to complete enrollment in its ongoing MultiSense CRT-D monitoring study.

Boston Scientific [1] (NYSE:BSX [2]) needs some extra time to complete its MultiSense CRM monitoring study, the company told the Federal Communications Commission in requesting an extended waiver to access a restricted radiofrequency band.

The MultiSense trial, launched in 2010, combines the multi-sensor Cognis model cardiac resynchronization therapy defibrillator with Boston Scientific's Latitude patient management system, which wirelessly transmits data from the CRT-D to the patient's physician.